Somewhat Positive Press Coverage Somewhat Unlikely to Impact Alpine Immune Sciences (ALPN) Stock Price

News stories about Alpine Immune Sciences (NASDAQ:ALPN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alpine Immune Sciences earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.6541161040816 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

Shares of Alpine Immune Sciences traded up $0.17, reaching $7.02, during mid-day trading on Friday, according to Marketbeat.com. The company’s stock had a trading volume of 1,642 shares, compared to its average volume of 15,659. The stock has a market capitalization of $94.85 million, a price-to-earnings ratio of -5.85 and a beta of 0.55. The company has a quick ratio of 26.71, a current ratio of 26.70 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a 1-year low of $6.77 and a 1-year high of $12.87.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, May 14th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.02. The business had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.13 million. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 25.00%. equities research analysts expect that Alpine Immune Sciences will post -1.82 EPS for the current year.

A number of equities analysts have weighed in on ALPN shares. ValuEngine upgraded shares of Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. Oppenheimer started coverage on shares of Alpine Immune Sciences in a research report on Friday, June 29th. They set an “outperform” rating and a $13.00 price objective for the company. Citigroup started coverage on shares of Alpine Immune Sciences in a research report on Thursday, June 28th. They set an “outperform” rating and a $13.00 price objective for the company. Finally, Wedbush initiated coverage on shares of Alpine Immune Sciences in a research report on Thursday, May 17th. They set an “outperform” rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $12.75.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Article: Trading Strategy Methods and Types

Insider Buying and Selling by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply